RB1 and non-small cell lung carcinoma: Recent preclinical data support that Rb phosphorylation is maintained in the majority of NSCLC cell lines with either intrinsic or acquired resistance to osimertinib, and thereby, CDK4/6 inhibitors represent an emerging therapeutic option [105].